MoneyShow's Best Investment Ideas For 2026: Part 3 [Seeking Alpha]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Seeking Alpha
This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 3 of this series includes Ceragon Networks, Celldex Therapeutics, Constellation Energy, Coppernico Metals, Costco, and Dynex Capital, among others. PM Images/DigitalVision via Getty Images MoneyShow's top contributing analysts, strategists, and newsletter editors share their investment recommendations for the year ahead. See Part 2 here Celldex Therapeutics Inc. By John McCamant, Editor of Medical Technology Stock Letter We are This article was written by Quick Insights CLDX management expects barzolvolimab pricing and reimbursement to exceed the consensus $40,000/year, potentially approaching Dupixent's $60,000+, suggesting Street models and price targets may rise. Two Phase III trials for chronic urticaria are underway, with a food allergy trial likely in 2026; add
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics SVPs Engage In Heavy Transactions [Yahoo! Finance]Yahoo! Finance
- Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.MarketBeat
- Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic DermographismGlobeNewswire
CLDX
Earnings
- 11/10/25 - Miss
CLDX
Sec Filings
- 1/6/26 - Form 4
- 12/17/25 - Form 4
- 12/8/25 - Form 4
- CLDX's page on the SEC website